Advances in the treatment of MDS, multiple myeloma, and CLL

ONS Connect. 2007;22(8 Suppl):55-6.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Boronic Acids / adverse effects
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Drug Monitoring
  • Humans
  • Lenalidomide
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell / etiology
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / etiology
  • Multiple Myeloma / therapy*
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / etiology
  • Myelodysplastic Syndromes / therapy*
  • Nurse's Role
  • Oncology Nursing
  • Prognosis
  • Pyrazines / adverse effects
  • Pyrazines / therapeutic use
  • Risk Assessment
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Lenalidomide